Skip to main content

Advertisement

Table 1 Patient characteristics (ITT population)

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

Characteristics n (%)
Number of total patients 49  
Median age, years (range) 43 (27–60)
Menopausal status   
   Premenopause 42 (85.7%)
   Postmenopause 7 (14.3%)
Histology   
   Invasive ductal carcinoma 46 (93.9%)
   Invasive lobular carcinoma 1 (2.0%)
   Mixed type (ductal + lobular) 2 (4.1%)
ECOG performance status   
   0 25 (51.0%)
   1 24 (49.0%)
Prechemotherapy T stage   
   cT1 5 (10.3%)
   cT2 37 (75.5%)
   cT3 6 (12.2%)
   cT4 1 (2.0%)
Prechemotherapy N stage   
   cN0 0 (0.0%)
   cN1 30 (61.2%)
   cN2 14 (28.6%)
   cN3 5 (10.2%)
AJCC clinical stage   
   IIA 3 (6.1%)
   IIB 25 (51.0%)
   IIIA 16 (32.7%)
   IIIB 0 (0.0%)
   IIIC 5 (10.2%)
Median tumor size by palpation, cm (range) 4.0 (0–11.0)
Hormonal receptor status*   
   Positive for ER or PgR 36 (73.5%)
   Negative for ER and PgR 13 (26.5%)
HER2 status   
   Positive 0 (0.0%)
   Negative 49 (100%)
  1. ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PgR, progesterone receptor. *The cut-off of ER and PgR positivity was 10% stained cells by immunohistochemistry.